Table 1 Clinical and laboratory (BNP level) characteristics of normal controls and PAH patients
Variable | Control (n = 21) | PAH patients (n = 25) | P |
|---|---|---|---|
Age (y) | 10.97 ± 3.48 | 11.07 ± 3.44 | 0.821 |
Male (%) | 10 (47.61 %) | 11 (44.00 %) | 1.000 |
H (cm) | 147.50 (133.25,156.75) | 136 (119.00,147.00) | 0.081 |
W (kg) | 42.15 ± 18.15 | 29.95 ± 12.07 | 0.010 |
BSA (m2) | 1.29 ± 0.36 | 1.05 ± 0.27 | 0.012 |
BMI (m/kg2) | 18.31 ± 3.48 | 15.53 ± 2.97 | 0.016 |
6MWD (m) | 480.35 ± 55.03 | 413.66 ± 75.31 | 0.001 |
SpO2 before 6MWT (%) | 98.00 (95.20,98.90) | 85.71 ± 9.52 | 0.0001 |
SpO2 after 6MWT (%) | 98.00 (97.00,99.00) | 75.80 ± 15.59 | 0.0001 |
HR before 6MWT (bpm) | 86.15 ± 11.79 | 98.90 ± 14.38 | 0.190 |
HR after 6MWT (bpm) | 109.20 ± 14.84 | 114.90 ± 16.09 | 0.246 |
WHO Functional class 1/2/3/4 | NA | 0/15/9/1 0/60 %/36 %/4 % | |
BNP level (pg/ml) | 9.00 (10.48,16.34) | 25.85 (27.98,80.28) | 0.005 |
PAH type | |||
Idiopathic | NA | 5 (20 %) | NA |
Ventricular septal defect | NA | 12 (48 %) | NA |
Atrioventricular septal defect | NA | 5 (20 %) | NA |
Truncus arteriosus communis | NA | 3 (12 %) | NA |
Medication no(%) | |||
Sildenafil | NA | 5 (20 %) | NA |
Bosentan | NA | 13 (52 %) | NA |
Combination (Sildenafil + Bosentan) | NA | 7 (28 %) | NA |